Additional Share Buyback Programme
Company announces additional share buyback programme of up to £1.0m following successful initial programme.
- Additional buyback programme c.£1.0m
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that following the successful conclusion of the initial share buyback programme, confirmed on 13 May 2025, the Company intends to conduct additional on-market purchases of ordinary shares of 1p each in the Company ("Ordinary Shares") of up to a further c.£1.0m, pursuant to the authorities obtained at the Company's last annual general meeting held on 20 May 2025. Any Ordinary Shares repurchased will be held in treasury.
Christopher Mills, Non-Executive Director of the Company, is the Chief Investment Officer of Harwood Capital Management (Gibraltar) Limited ("Harwood"), which is investment manager to Oryx International Growth Fund Limited ("Oryx") and Chief Investment Officer of North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). Mr. Mills is a director and shareholder in Oryx and also a director and shareholder in NASCIT. Oryx and NASCIT hold 36,544,396 and 95,088,797 Ordinary Shares, respectively, and 132,433,193 Ordinary Shares in aggregate (with 800,000 Ordinary Shares held by Harwood Capital LLP), which is equivalent to approximately 29.49% of the current total voting rights in the Company. Harwood will facilitate the participation of these entities in the share buy back pro rata to their existing aggregate holding, with the intention that the aggregate indirect beneficial interest of Mr. Mills remains at approximately this level and in any event does not exceed 30.00% of the prevailing total voting rights in the Company following any repurchases. This is solely in order for Mr. Mills and the above connected entities (which are, unless otherwise established, deemed to be acting in concert in accordance with the City Code on Takeovers and Mergers) to avoid otherwise being subject to an obligation under the City Code on Takeovers and Mergers to make a mandatory offer for the Company's entire share capital or to obtain the requisite shareholder approval for a waiver from the Takeover Panel from such obligation.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
| Julian Baines, Executive Chair | via Walbrook PR |
| Gavin Jones, Chief Executive Officer | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 |
| Phil Davies / Oliver Platts | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.